Toxicity profile of bevacizumab in the UK Neurofibromatosis type 2 cohort
Author:
Funder
National Institute for Health Research
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Clinical Neurology,Neurology,Oncology
Link
http://link.springer.com/content/pdf/10.1007/s11060-016-2276-9.pdf
Reference23 articles.
1. Mautner VF, Nguyen R, Kutta H, Fuensterer C, Bokemeyer C, Hagel C, Friedrich RE, Panse J (2010) Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro-Oncol 12(1):14–18. doi: 10.1093/neuonc/nop010
2. Plotkin SR, Stemmer-Rachamimov AO, Barker FG 2nd, Halpin C, Padera TP, Tyrrell A, Sorensen AG, Jain RK, di Tomaso E (2009) Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 361(4):358–367. doi: 10.1056/NEJMoa0902579
3. Plotkin SR, Merker VL, Halpin C, Jennings D, McKenna MJ, Harris GJ, Barker FG, 2nd (2012) Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neuro 33 (6):1046–1052. doi: 10.1097/MAO.0b013e31825e73f5
4. Alanin MC, Klausen C, Caye-Thomasen P, Thomsen C, Fugleholm K, Poulsgaard L, Lassen U, Mau-Sorensen M, Hofland KF (2014) The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2. Eur Arch Oto-Rhino-Laryngol. doi: 10.1007/s00405-014-3398-3
5. Hochart A, Gaillard V, Baroncini M, Andre N, Vannier JP, Vinchon M, Dubrulle F, Lejeune JP, Vincent C, Neve V, Sudour Bonnange H, Bonne NX, Leblond P (2015) Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2. J Neurooncol 124(2):229–236. doi: 10.1007/s11060-015-1828-8
Cited by 38 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Fibroblasts Derived From Vestibular Schwannoma Express Protumorogenic Markers;Otology & Neurotology;2023-09-15
2. Treatment of neurofibromatosis type II with anlotinib: a case report and literature review;Anti-Cancer Drugs;2023-01-24
3. A systematic review of targeted therapy for vestibular schwannoma in patients with NF2-related schwannomatosis;Neuro-Oncology Advances;2023-01-01
4. Phase II trial of icotinib in adult patients with neurofibromatosis type 2 and progressive vestibular schwannoma;Journal of Neurosurgery;2022-10-01
5. Qu-Du-San-Jie decoction induces growth inhibition and vascular normalization in NF2-associated vestibular schwannoma;Frontiers in Pharmacology;2022-08-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3